ALK-Abelló A/S (LON:0OIR)

Market Cap	5.49B +41.7%
Revenue (ttm)	710.34M +12.9%
Net Income	128.67M +40.3%
EPS	0.58 +41.8%
Shares Out	n/a
PE Ratio	42.64
Forward PE	34.85
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,614
Average Volume	25,337
Open	213.80
Previous Close	213.30
Day's Range	213.20 - 215.40
52-Week Range	131.30 - 237.60
Beta	0.58
RSI	12.55
Earnings Date	Feb 20, 2026

About ALK-Abelló

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mites, grass and tree pollen, ragweed, Japanese cedar, and food. It also provides consumer healt...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1923
• Employees: 2,764
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0OIR

Financial Performance

In 2024, ALK-Abelló's revenue was 5.54 billion, an increase of 14.78% compared to the previous year's 4.82 billion. Earnings were 815.00 million, an increase of 67.70%.

Financial numbers in DKK